ClinicalTrials.gg
CompletedNCT05216926PBH ForecastUpdated Jun 12, 2024

Forecasting and Preventing Post-Bariatric Hypoglycaemia WP 3

An interventional study of Timing of preventive action based on prediction model and Hypoglycaemia treatment at hypoglycaemia (usual care) in Post-bariatric Hypoglycaemia and Roux-en-Y Gastric Bypass, sponsored by Lia Bally. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-12.

Sponsored by Lia Bally · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The overall aim of this study is to prevent hypoglycemic events in patients with hypoglycemia after a meal and to develop a sustainable hypoglycemia correction strategy.

Read the detailed description

Obesity is a major global public health concern, for which the most effective therapy is bariatric surgery. Beyond weight loss, bariatric surgery exerts powerful effects on glucose metabolism, achieving complete type 2 diabetes remission in up to 70% of cases. An exaggeration of these effects, however, can result in an increasingly recognized metabolic complication known as postprandial hyperinsulinaemic hypoglycaemia or post-bariatric hypoglycaemia (PBH). The condition manifests 1-3 years after surgery with meal-induced hypoglycaemic episodes. Emerging data suggests that PBH is more frequent than previously thought and affects approximately 30% of postoperative patients, more commonly after gastric bypass than sleeve gastrectomy. Of note, asymptomatic PBH is common, as shown in studies using continuous glucose monitoring (CGM). It is known from extensive research in people with diabetes that recurrent episodes of hypoglycaemia impair counter regulatory defences against subsequent events, predisposing patients to severe hypoglycaemia.

Despite the increasing prevalence of PBH, clinical implications in this population are still unclear. Anecdotal evidence from patients with PBH suggests a high burden for these patients due to the recurrent hypoglycaemias with possibly debilitating consequences. It is well established that even mild hypoglycaemia (plasma glucose of 3.4 mmol/L) in diabetic and non-diabetic patients impairs various cognitive domains. Of note, some of the cognitive functions remain impaired for up to 75 min, even when the hypoglycaemia is corrected. Further concerns exist from observational studies showing associations between PBH during pregnancy and poor foetal growth.

Thus, it is important to timely detect and treat hypoglycaemia with an intervention that allows quick recovery of glycaemia to a safe level, thereby alleviating symptoms and eliminating the risk of potentially hazardous sequelae. Recently, CGM devices have become standard tools for glucose monitoring in patients with diabetes. CGM allows measuring glucose levels every 5 min and the continuous access to real-time data offering several approaches for the prediction of glucose levels or associated events. Such solutions empower patients to take proactive decisions before reaching critical glucose levels. Apart from glucose levels, meal information, physical activity or other physiological parameters may augment prediction performance of hypoglycaemic events. While most engineering work focuses on the prediction of hypoglycaemia in the diabetic population, only preliminary work has been done in the PBH population.

Given the potentially hazardous consequences of hypoglycaemia, development of hypoglycaemia management strategies to adequately predict and treat critical blood glucose levels in the PBH population are urgently needed. Such strategies have to significantly lower the burden of PBH and increase patient safety.

The overall aim or this study is to prevent hypoglycaemic events in patients with PBH and to develop a sustainable hypoglycaemia correction strategy.

The primary objective of WP 3 is to test the efficacy of an intervention for hypoglycaemia prevention that combines a hypoglycaemia prediction model with a preventive nutritional action.

02

Conditions studied

  • Post-bariatric Hypoglycaemia
  • Roux-en-Y Gastric Bypass

Keywords

  • Continuous Glucose Monitoring
03

In context

Lead sponsor

Lia Bally is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Post-bariatric surgery patients (Roux-en-Y gastric bypass) with PBH, defined as postprandial plasma or sensor glucose \<3.0 mmol/L according to the International Hypoglycaemia Study Group and exclusion of other causes of hypoglycaemia
  • Age ≥18 years

Exclusion criteria

Exclusion Criteria:

  • Inability to give as documented by signature
  • Pregnant or lactating women
  • Inability or to undergo the investigated intervention
  • Drugs interfering with blood glucose (e.g. SGLT-2 inhibitors, acarbose) during the time of investigation
  • Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Hypoglycemia predicition and preventive treatment

    Other: Timing of preventive action based on prediction model

  • Other
    Corrective hypoglycemia treament (at hypogylcemia)

    Other: Hypoglycaemia treatment at hypoglycaemia (usual care)

Interventions

  • OtherTiming of preventive action based on prediction model

    Timing of preventive action based on prediction model

  • OtherHypoglycaemia treatment at hypoglycaemia (usual care)

    Hypoglycaemia treatment at hypoglycaemia (usual care)

06

What researchers measure

Primary outcomes

  1. Hypoglycaemia

    Proportion of participants with hypoglycaemia (nadir plasma glucose \<3.0 mmol/L)

    Time frame: In the 180 minutes following the beginning of meal intake

Secondary outcomes

  1. Plasma glucose <3.0 mmol/L

    Percentage of post-prandial time with plasma glucose \<3.0 mmol/L

    Time frame: During 180 minutes following the beginning of meal intake

  2. Plasma glucose <3.9 mmol/L

    Percentage of post-prandial time with plasma glucose \<3.9 mmol/L

    Time frame: During 180 minutes following the beginning of meal intake

  3. Plasma glucose ≥10.0 mmol/L

    Percentage of post-prandial time with plasma glucose ≥10.0 mmol/L

    Time frame: During 180 minutes following the beginning of meal intake

  4. Mean plasma glucose

    Mean plasma glucose concentration

    Time frame: During 180 min following onset of meal intake

  5. Peak plasma glucose

    Peak plasma glucose

    Time frame: In the 180 min following onset of meal intake

07

Study locations

1 site
  • Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism (UDEM), Inselspital, Bern University Hospital
    Bern, BE 3010, Switzerland
08

References and documents

Individual participant data

Plan to share: Yes — All IPD that underlie results in a publication will be available to other researchers.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After study completion, 10 years

Access criteria: After written inquiry and approval by the principal investigator.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in May 2024, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2022
First posted
Feb 1, 2022
StartActual
Jan 18, 2022
Primary completionActual
May 7, 2024
CompletionActual
May 31, 2024
Last update
Jun 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05216926
Lead sponsor
Lia Bally
Responsible party
Lia Bally (Head of Nutrition, Metabolism and Obesity and Head of Research, Insel Gruppe AG, University Hospital Bern) — Sponsor-investigator
First posted
Feb 1, 2022
Start date
Jan 18, 2022
Primary completion
May 7, 2024
Completion
May 31, 2024
Last update
Jun 12, 2024

Study contacts

Lia Bally, Prof. Dr. med. et phil.
principal investigator · Department of Diabetes, Endocrinology, Nutritional Medicine and Metabolism, lnselspital, Bern University Hospital, University of Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion